Andere Sprachen Affimed N.V.

Aktien

A407ZR

NL0015001ZQ0

AFMD

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 18.04.2024			% 5 Tage	% 1. Jan.
5.07 ^USD	-3.06%		-14.21%	-18.88%

01.04.	AFFIMED N.V. : erhält Kaufen-Rating von Wells Fargo Securities	ZM
01.04.	AFFIMED N.V. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Affimed Reports 2023 Financial Results and Operational Progress	28.03.
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	21.03.
Affimed N : Form 6-K	11.03.
Affimed Announces 1-for-10 Reverse Stock Split	06.03.
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING	09.01.
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	08.01.
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer	08.01.
Affimed Announces Leadership Change and Organizational Restructuring	08.01.
Affimed N.V. Announces CEO Changes	08.01.
Affimed N.V. Announces Management Changes	08.01.
Sector Update: Health Care Stocks Mixed Late Afternoon	03.01.
Sector Update: Health Care Stocks Gain in Afternoon Trading	03.01.
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall	03.01.
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	03.01.
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.	03.01.
Affimed N.V.(NasdaqCM:AFMD) dropped from NASDAQ Biotechnology Index	15.12.
AFFIMED ANNOUNCES UPDATED PHASE DATA FROM ACIMTAMIG IN COMBINATION WITH ALLOGENEIC NK IN HODGKIN LYMPHOMA PATIENTS WHO FAILED PRIOR CHEMOTHERAPY AND ARE DOUBLE-REFRACTORY TO BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITORS	12.12.
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	11.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Affimed N.V.

Aktien

A407ZR

NL0015001ZQ0

AFMD

Andere Sprachen

Filter